Work

MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.9068

Authors: Romel Somwar, Roger Smith, Takuo Hayashi, Kota Ishizawa, Alexandra Snyder Charen, Inna Khodos, Marissa Mattar, Jie He, Sohail Balasubramanian, Phil Stephens, Doron Lipson, Elisa de Stanchina, Monika Davare, Vincent A. Miller, Gregory J. Riely, Charles M. Rudin, Mark G. Kris, Emily Cheng, Marc Ladanyi, Alexander E. Drilon

Institutions: Memorial Sloan Kettering Cancer Center, Foundation Medicine (United States), Oregon Health & Science University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891377230

Cites:

Cited by: 20

Related to: 10